Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Preclinical Models for Assessing Thrombocytopenia and Neutropenia Risk with ADCs

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Models for Assessing Thrombocytopenia and Neutropenia Risk with ADCs

Preclinical Models for Assessing Thrombocytopenia and Neutropenia Risk with Targeted Cytotoxic Conjugates

CELL & GENE | RNA | BIOLOGICS

Hematologic dose-limiting toxicities, particularly thrombocytopenia and neutropenia, represent a primary obstacle in the clinical development of antibody-based cytotoxic payloads. Successful navigation from discovery to an IND submission requires preclinical toxicology programs designed to predict and characterize these specific on-target and off-target liabilities. The selection of a translationally relevant toxicology species is a foundational step, demanding a rigorous evaluation of target biology, payload pharmacology, and hematopoietic system homology to generate a predictive safety profile.

    What are the primary hematologic toxicities for targeted cytotoxic payloads?

    A: The most common dose-limiting toxicities are thrombocytopenia (low platelet count) and neutropenia (low neutrophil count), often stemming from payload-mediated effects on hematopoietic stem and progenitor cells (HSPCs) or mature hematopoietic lineages.

    Why are standard nonclinical models often insufficient for this modality?

    A: Predictive accuracy is challenged by species-specific differences in target expression on hematopoietic cells, variations in payload metabolism, and differential sensitivity of hematopoietic progenitors to the cytotoxic agent. A generic approach is rarely sufficient.

    How does Franklin Biolabs select the most relevant species?

    A: Species selection is a data-driven process based on target homology analysis, payload pharmacology, and in vitro cross-reactivity assessments against primary cells from candidate species to confirm biological relevance before initiating in vivo studies.

    What is the typical IND timeline for a program involving these studies?

    A: For complex biologics requiring extensive safety characterization, sponsors should anticipate an 18-24 month IND timeline from the initiation of pivotal toxicology studies to regulatory submission.

The Challenge of Hematologic DLTs in Conjugate Development

Hematologic toxicities are a well-documented class effect for many conjugate therapeutics. These adverse events can arise from several mechanisms: on-target toxicity on hematopoietic progenitors expressing the target antigen, non-specific uptake of the cytotoxic payload by these sensitive cells, or broader disruption of the bone marrow niche.

Distinguishing between these potential mechanisms is a core objective of the preclinical safety program. An effective strategy involves designing studies that can isolate variables and provide clear, interpretable data on the drivers of toxicity, enabling informed decisions on clinical starting dose and risk mitigation.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Selecting Translationally Relevant Preclinical Systems

The predictive value of any nonclinical toxicology study hinges on the relevance of the chosen biological system. For targeted cytotoxic conjugates, assuming that a single model will be universally informative is a significant program risk. Predictive accuracy requires a model that faithfully recapitulates the three key biological components of the therapeutic: the antibody, the linker, and the payload.

Key sources of inter-species variability that must be characterized include:

  • Target Expression: The antigen target may have different expression levels or patterns on hematopoietic cells in nonclinical species compared to humans.

  • Payload Sensitivity: Hematopoietic progenitors from different species can exhibit varied intrinsic sensitivity to the cytotoxic payload.

  • Metabolism and Pharmacokinetics: Differences in linker stability and payload metabolism can significantly alter the exposure profile and resulting toxicity.

A systematic approach to model selection, integrating in silico analysis with in vitro functional data, is necessary to justify the use of a particular species for pivotal safety assessment.

Consideration Rodent Models Non-Human Primate (NHP) Models
Target Homology Variable; requires sequence analysis and expression confirmation. High degree of homology with human hematopoietic system.
Payload Metabolism May differ significantly from human metabolic pathways. Generally more predictive of human pharmacokinetics and metabolism.
Reagents & Tooling Widely available commercial and custom reagents. More limited and specialized reagent availability.
Operational Scale Suitable for early screening and dose-range finding. Reserved for pivotal, IND-enabling GxP safety studies.

A Commitment to Enhanced Responsibility

Our programs are designed to maximize data quality while adhering to the highest ethical standards, including the 3Rs (Reduce, Refine, Replace) of animal research. All studies are conducted in our AAALAC-accredited and USDA-registered facilities.

[Video Playback: FBL-VID-09-Approved_enhanced_responsibility_clip_long.mp4]

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Integrated Bioanalytical and Histology Support

In vivo observations are only as valuable as the data used to interpret them. Our toxicology programs are supported by dedicated bioanalytical teams to develop and validate assays for quantifying conjugate exposure and payload release kinetics. These data are correlated with findings from our GxP-compliant Histology core.

Within our >100,000 sq ft facility, our board-certified pathologists evaluate bone marrow smears and tissue sections to provide definitive assessments of cellularity, lineage-specific effects, and non-target tissue biodistribution. This integrated approach provides the data needed to make confident, forward-looking program decisions.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities